Literature DB >> 20481404

Confronting conflict: addressing institutional conflicts of interest in academic medical centers.

Bryan A Liang1, Tim Mackey.   

Abstract

Individual conflicts of interest are rife in healthcare, and substantial attention has been given to address them. Yet a more substantive concern-institutional conflicts of interest ("ICOIs") in academic medical centers ("AMCs") engaged in research and clinical care-have yet to garner sufficient attention, despite their higher stakes for patient safety and welfare. ICOIs are standard in AMCs, are virtually unregulated, and have led to patient deaths. Upon review of ICOIs, we find a clear absence of substantive efforts to confront these conflicts. We also assess the Jesse Gelsinger case, which resulted in the death of a study participant exemplifying a deep-seated culture of institutional indifference and complicity in unmanaged conflicts. Federal policy, particularly the Bayh-Dole Act, also creates and promotes ICOIs. Efforts to address ICOIs are narrow or abstract, and do not provide for a systemic infrastructure with effective enforcement mechanisms. Hence, in this paper, we provide a comprehensive proposal to address ICOIs utilizing a "Centralized System" model that would proactively review, manage, approve, and conduct assessments of conflicts, and would have independent power to evaluate and enforce any violations via sanctions. It would also manage any industry funds and pharmaceutical samples and be a condition of participation in public healthcare reimbursement and federal grant funding. The ICOI policy itself would provide for disclosure requirements, separate management of commercial enterprise units from academic units, voluntary remediation of conflicts, and education on ICOIs. Finally, we propose a new model of medical education-academic detailing-in place of current marketing-focused "education." Using such a system, AMCs can wean themselves from industry reliance and promote a culture of accountability and independence from industry influence. By doing so, clinical research and treatment can return to a focus on patient care, not profits.

Entities:  

Mesh:

Year:  2010        PMID: 20481404     DOI: 10.1177/009885881003600103

Source DB:  PubMed          Journal:  Am J Law Med        ISSN: 0098-8588


  6 in total

1.  Investigating research and accessing reproductive material.

Authors:  Trudo Lemmens; Bernadette J Richards
Journal:  J Bioeth Inq       Date:  2014-01-04       Impact factor: 1.352

2.  Prevalence and Global Health implications of social media in direct-to-consumer drug advertising.

Authors:  Bryan A Liang; Timothy K Mackey
Journal:  J Med Internet Res       Date:  2011-08-31       Impact factor: 5.428

3.  The rise of digital direct-to-consumer advertising?: Comparison of direct-to-consumer advertising expenditure trends from publicly available data sources and global policy implications.

Authors:  Tim K Mackey; Raphael E Cuomo; Bryan A Liang
Journal:  BMC Health Serv Res       Date:  2015-06-19       Impact factor: 2.655

4.  A call for a moratorium on the .health generic top-level domain: preventing the commercialization and exclusive control of online health information.

Authors:  Tim K Mackey; Gunther Eysenbach; Bryan A Liang; Jillian C Kohler; Antoine Geissbuhler; Amir Attaran
Journal:  Global Health       Date:  2014-09-26       Impact factor: 4.185

5.  The disease of corruption: views on how to fight corruption to advance 21st century global health goals.

Authors:  Tim K Mackey; Jillian Clare Kohler; William D Savedoff; Frank Vogl; Maureen Lewis; James Sale; Joshua Michaud; Taryn Vian
Journal:  BMC Med       Date:  2016-09-29       Impact factor: 8.775

6.  How Do Institutional Conflicts of Interest Between Pharmaceutical Companies and the Healthcare Sector Become Corrupt? A Case Study of Scholarship Donations Between Department of Clinical Anesthesiology, Mie University, and Ono Pharmaceutical in Japan.

Authors:  Akihiko Ozaki; Anju Murayama; Kayo Harada; Hiroaki Saito; Toyoaki Sawano; Tetsuya Tanimoto; Piotr Ozieranski
Journal:  Front Public Health       Date:  2022-01-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.